Products
BIA 10-2474 is in clinical development at the Portuguese pharmaceutical company Bial. It is not commercially available.
Structure and properties
BIA 10-2474 is the following urea and imidazole derivative:
Effects
BIA 10-2474 is a long-acting inhibitor of the enzyme FAAH (fatty acid amide hydrolase). This enzyme is involved in the breakdown of fatty acid amides such as anandamide, an endogenous cannabinoid found primarily in the brain. FAAH degrades anandamide to ethanolamine and arachidonic acid. Anandamide is an agonist at cannabinoid receptors. Inhibition of FAAH enhances the effects of endogenous anandamide and other fatty acid amides.
Indications
For the treatment of neurologic and psychiatric disorders.
Adverse effects
A serious adverse event occurred in a phase I trial of BIA 10-2474 in Rennes, France, in January 2016. Six subjects required hospitalization with neurologic complaints. One subject had suffered brain death and died.
